Phase I
It was another busy week for clinical trial updates and news. Here’s a look.
Finding and developing an effective treatment for nonalcoholic steatohepatitis has, so far, been met with as much futility and frustration as developing a treatment for Alzheimer’s disease. Sagimet Biosciences Chief Executive Officer George Kemble believes his company is on the right path, though.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 20, 2020.
Intellia has received approval to launch their Phase I trial of NTLA-2001 in hereditary ATTR.
It was another busy week for both COVID-19-related clinical trial news as well as trial updates for other indications. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 13, 2020.
It was a moderately busy week for clinical trial news. Here’s a look.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for October 6, 2020.
Biopharma companies wrapped up September and headed into October with plenty of clinical trial news. Here’s a look.
PF-06939926 is currently being evaluated to determine the safety and efficacy of this gene therapy in boys with DMD.
PRESS RELEASES